Glycyx Alternatives & Competitors
12 companies similar to Glycyx — Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency t...
Avacta Therapeutics
Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
London, United Kingdom
Prelude Therapeutics
Precision Oncology, Redefined.
Wilmington, United States
RayzeBio
Targeted innovative radiopharmaceuticals for cancer
San Diego, United States
iOmx Therapeutics AG
Developing next-generation targeted cancer immunotherapy treatments
Germany
Track all Glycyx competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Neogene Therapeutics
Pushing the frontier by pioneering next-generation engineered T cell receptor therapies fo...
Amsterdam, The Netherland...
Xilio Therapeutics, Inc.
Focused on harnessing the immune system to achieve deep and durable clinical responses to...
Waltham, United States
Duo Oncology
Nanomedicines as the foundation of cancer medicine. Platform chemistry designed for patie...
Pittsburgh, United States
Precirix
Precision radiopharmaceuticals
Brussels, Belgium
Teon Therapeutics Inc.
Teon is a clinical company targeting metabolic signaling pathways and pioneering the devel...
Redwood City, United Stat...
ARTBIO
Channeling Energy. Changing Lives.
Cambridge, United States
Clasp Therapeutics
Pioneering precise immuno-oncology with next-gen T cell engagers targeting specific tumor...
FREZENT Biological
Preventing cancer recurrence
New York, United States
About Glycyx
Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy
Development of therapies that restore immune function, Combination treatments with immune checkpoint inhibitors, Enhanced T-cell infiltration into tumors, Inhibition of opioid-induced immune suppression
Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies
Cancer Treatment, Immunotherapy, Opioid-Induced Immunodeficiency, Immune Checkpoint Inhibitors, Peripherally Restricted Opioid Antagonist, Phase 2 Clinical Trials, Tumor Microenvironment, Non-Small Cell Lung Cancer, Head And Neck Cancer, Hepatocellular Cancer, Immuno-oncology, Therapeutics, Oncology, Clinical Development
B2B, B2D
Licensing, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Glycyx and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Glycyx on 11 Mar 2026. The 12 companies listed here were last checked between 27 Nov 2025 and 11 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.